Drugs / DA-2811-R2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07239440 Background | Nov 2025 → Dec 2026 expected | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-2811-R2 | “DA-2811 + DA-2811-R2, orally, once daily” NCT07239440 ↗ |
| Route | Oral | “DA-2811 + DA-2811-R2, orally, once daily” NCT07239440 ↗ |